FDA approves first of two UCB myasthenia gravis drugs, following Alexion and argenx’s lead
The FDA approved UCB’s generalized myasthenia gravis treatment Rystiggo, with the Belgian drugmaker saying it is the first drug to get OK’d for the two …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
